Suscripción a Biblioteca: Guest
Critical Reviews™ in Oncogenesis

Publicado 4 números por año

ISSN Imprimir: 0893-9675

ISSN En Línea: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

The Role of Oncogenic DNA Viruses in Penile Cancer Development

Volumen 24, Edición 4, 2019, pp. 385-402
DOI: 10.1615/CritRevOncog.2020032961
Get accessGet access

SINOPSIS

Penile cancer is a relatively rare neoplasia in developed countries, with significant morbidity and mortality in developing countries. Penile cancer can be subdivided into human papillomavirus (HPV)-positive and HPV-negative cases. Worldwide, the HPV prevalence in penile cancer samples is around 50%, and HPV16 is the most prevalent genotype. Although HPV is an important factor for cancer development, other oncogenic factors may be associated with carcinogenesis. Some of these factors can be infectious, such as the Epstein-Barr virus (EBV), as well as the Merkel cell polyomavirus (MCPyV). The prevalence rates of nearly 50% for both HPV and EBV infections indicate an important role of these viruses in penile tissue malignancy, reinforcing the idea of a multifactorial etiology of the disease. Although the HPV role is better understood, EBV is thought to facilitate persistence, integration, and mutations. Recent studies on the Merkel cell polyomavirus have not shown a relevant prevalence in penile cancer samples, but its presence indicates the opportunistic infectious potential of this virus. Regarding HPV-negative cases, the literature suggests a link with younger age and epigenetic alterations, mainly through the p16INK4a pathway. Recently, several biomarkers that might act as prognostic tools (e.g., Ki-67, squamous cell carcinoma antigen, among others) have been proposed, but the results remain controversial. In addition, other risk factors have also been associated with penile carcinogenesis, such as the presence of phimosis, noncircumcision, chronic inflammation, and number of sexual partners. Further studies are needed to develop tools for early detection and epidemiological surveillance of penile cancer.

PALABRAS CLAVE: HPV, EBV, MCPyV, penile cancer
REFERENCIAS
  1. Rubin MA, Kleter B, Zhou M, Ayala G, Cubilla AL, Quint WG, Pirog EC. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol. 2001;159:1211-18.

  2. WHO/ICO Information Centre on HPV and Cervical Cancer. Human papillomavirus and related cancers in Brazil. Summary Report; 2019.

  3. Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, Giuliano AR. Incidence trends in primary malignant penile cancer. Urol Oncol. 2007;25(5):361-67.

  4. Nuovo GJ, Hochmann HA, Eliezra YD, Lastarria D, Comite SL, Silvers DN. Detection of human papillomavirus DNA in penile lesions histologically negative for condylomata. Am J Surg Pathol. 1990;14:829-36.

  5. Maden C, Sherman KJ, Beckmann AM, Hislop TG, Teh CZ, Ashley RL, Daling JR. History of circumcision, medical conditions and sexual activity and risk of penile cancer. J Natl Cancer Institute. 1993;85:19-24.

  6. Afonso LA, Moyses N, Alves G, Ornellas AA, Passos MR, Cavalcanti SMB. Prevalence of human papillomavirus and Epstein-Barr virus DNA in penile cancer cases from Brazil. Memorias Instituto Oswaldo Cruz. 2012;107:18-23.

  7. Mirrales-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, Sanjose S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol. 2009;62(10):870-78.

  8. Pow-Sang VB, Pow-Sang JE, Morante C, Meza L, Baker M, Pow-Sang JM. Cancer of the penis. Cancer Control. 2002;9(4):305-14.

  9. Pow-Sang M, Astigueta J. HPV infection and the risk of penile cancer. J Androl Sci. 2009;16:1-14.

  10. Hernandez BY, Wilkens LR, Zhu X, Thompson P, Mc-Duffe K, Shvetsov YB, Kamemoto LE, Killeen J, Ning L, Goodman MT. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis. 2008;14:888.

  11. Afonso LA,Carestiato FN, Ornellas AA, Ornellas P, Rocha WM, Cordeiro TI, Lisboa DC, Alves GB, Cavalcanti SMB. Human papillomavirus, Epstein-Barr virus, and methylation status of p16ink4a in penile cancer. J Med Virol. 2017;89:1837-43.

  12. Szostek S, Zawilinska B, Kopec J, Kosz-Vnenchak M. Herpesviruses as possible cofactors in HPV-16-related oncogenesis. Acta Biochimica Polonica. 2009; 56(2):337-342.

  13. Alves G, Macrini CMT, Nascimento PS, Morais JC, Ornellas AA. Detection and expression of Epstein-Barr Virus (EBV) DNA in tissue from penile tumors in Brazil. Cancer Lett. 2004;215:79-82.

  14. Lam KY, Chan ACL, Chan KW, Leung ML, Srivastava G. Absence of Epstein-Barr virus in penile carcinoma. A study of 42 cases using in situ hybridization. Cancer. 1995;76(4):658-60.

  15. Crawford DH, Swerdlow AJ, Higgins C, McAulay K, Harrison N, Williams H, Britton K, Macsween KF. Sexual history and Epstein-Barr virus infection. J Infect Dis. 2002;186:731-36.

  16. Voog E. Genital viral infections. Studies on human papillomavirus and Epstein-Barr virus. Acta Dermato-Venereologica Suppl. 1996;198:1-55.

  17. Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD, Lotze MT. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exper Med. 1995;182:477-86.

  18. Prayitno A. Cervical cancer with human papilloma virus and Epstein Barr virus positive. J Carcinogen. 2006;5:13-16.

  19. Kulis M, Esteller M. DNA methylation and cancer. Adv Gen. 2010;70:27-56.

  20. Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol. 2009;27: 141-50.

  21. Ferreux E, Lont AP, Horenblas S, Gallee MPW, Raaphorst FM, Doeberitz MV, Meijer CJLM, Snijders PJF. Evidence for at least three alternative mechanisms targeting the 16(INK4A)/Cyclin D/Rb Pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Pathol. 2003;201(1):109-18.

  22. Cubilla AL, Velazques EF, Reuter VE, Oliva E, Mihm MC Jr, Young RH. Warty (condylomatous) squamous cell carcinoma of the penis: a report of 11 cases and proposed classification of 'verruciform' penile tumors. Am J Surg Pathol. 2000;24(4):505-12.

  23. Zargar-Shoshtari K, Spiess PE, Berglund AE, Sharma P, Pow Sang JM, Giuliano A, Magliocco AM, Dhillon J. Clinical significance of p53 and p16ink4a status in a contemporary North American penile carcinoma cohort. Clin Genitourinary Cancer. 2016;14(4):346-51.

  24. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nature Rev Cancer. 2006;6(2):107-16. 36.

  25. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nature Rev Gen. 2006;7:21-33.

  26. Zargar-Shoshtari MB, Sharma P, Spiess PE. Insight into novel biomarkers in penile cancer: redefining the present and future treatment paradigm? Urol Oncol. 2017; 36:433-39.

  27. Baez CF, Rocha WM, Afonso LA, Carestiato FN, Guimaraes MAAM, Cavalcanti SMB, Varella RB. First report of three major oncogenic viruses: human papillomavirus, Epstein-Barr virus and merkel cell polyomavirus in penile cancer. J Infect Dis Ther. 2015;3(5):1-2.

  28. Rocha WM. Etiological study of penile cancer: association of human papillomavirus, Epstein-Barr virus and Merkel cell polyomavirus [dissertation]. Universidade Federal Fluminense, Rio de Janeiro, Brazil; 2019.

  29. Dillner J, Von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl. 2000;205:189-93.

  30. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK, Krieger JN. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer. 2005;116:606-16.

  31. Tyring SK. Human papillomavirus infections: epidemiology, pathogenesis, and host immune response. J Am Acad Dermatol. 2000;43:518-26.

  32. Burd EM. Human papillomavirus laboratory testing: the changing paradigm. Clin Microbiol Rev. 2016;29(2): 291-318.

  33. Zaravinos A, Kanellou P, Spandidos DA. Viral DNA detection and RAS mutations in actinic keratosis and non-melanoma skin cancers. Br J Dermatol. 2010;162:325-31.

  34. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1-17.

  35. Sarkar FH, Miles BJ, Plieth DH, Crissman JD. Detection of human papillomavirus in squamous neoplasm of the penis. J Urol. 1992;147:389-92.

  36. Zur Hausen H. Papillomaviruses causing cancer: evasion from host cell control in carcinogenesis. J Natl Cancer Inst. 2000;92(9):690-98.

  37. Rintala MA, Pollanen PP, Nikkanen VP, Grenman SE, Syrjanen SM. Human papillomavirus DNA is found in the vas deferens. J Infect Dis. 2002;185:1664-67.

  38. Centers for Disease Control and Prevention. Prevention of genital human papillomavirus infection. Gerberding JL, director. Department of Health and Human Services. Report to Congress; 2004.

  39. Munoz N, Castellsague X, Gonzalez AG, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24:S1-S10.

  40. Gonzalez-Bosquet E, Munoz A, Sunol M, Lailla JM. Cervical cancer and low-risk HPV: a case report. Eur J Gynaecol Oncol. 2006;27(2):193-94.

  41. Fehrmann F, Laimins LA. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene. 2003;22:5201-7.

  42. Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol. 1995;69:2989-97.

  43. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci U S A. 1995;92:1654-58.

  44. Brenna SM, Syrjanen KJ. Regulation of cell cycles is of key importance in human papillomavirus (HPV)-associated cervical carcinogenesis. Sao Paulo Med J. 2003;121:128-32.

  45. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev Cancer. 2002;2:342-50.

  46. Amaro-Filho SM, Chaves CBP, Felix SP, Basto DL, de Almeida LM, Moreira MAM. HPV DNA methylation at the early promoter and E1/E2 integrity: a comparison between HPV16 HPV18 and HPV45 in cervical cancer. Papillomavirus Res. 2018;5:172-79.

  47. Carestiato FN, Amaro Filho SM, Moreira MAM, Cavalcanti SMB. Methylation ofp16ink4a promoter is independent of human papiomavirus DNA physical state: a comparison between cervical pre-neoplastic and neoplastic sample. Memorias Instituto Oswaldo Cruz. 2019;114.

  48. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24(Suppl S1):16-S22.

  49. Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol. 2005;32(Suppl 1):S72-S81.

  50. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009;9(6):347-56.

  51. Zhang B, Li P, Wang E, Brahmi Z, Dunn KW, Blum JS, Roman A. The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma. Virology. 2003;310:100-8.

  52. Matthews K, Leong CM, Baxter L, Inglis E, Yun K, Back-strom BT, Doorbar J, Hibma M. Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol. 2003;77:8378-85.

  53. Barnard P, Payne E, McMillan NA. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-a. Virology. 2000;277:411-19.

  54. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181: 1911-1919.

  55. Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis. 2002;186:1396-402.

  56. Svare EI, Kjaer SK, Nonnenmacher B, Worm AM, Moi H, Christensen RB, van den Brule AJ, Walboomers JM, Meijer CJ, Hubbert NL, Lowy DR, Schiller JT. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J Infect Dis. 1997;176:876-83.

  57. Slavinsky J, Kissinger P, Burger L, Boley A, Dicarlo R, Hagensee M. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS. 2001;12:516-23.

  58. Thompson DL, Douglas Jr JM, Foster M, Hagensee ME, Diguiseppi C, Baron AE, Cameron JE, Spencer TC, Zenilman J, Malotte CK, Bolan G, Kamb ML, Peterman TA. Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis. 2004;190:1563-74.

  59. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis. 2006;6(1):21-31.

  60. Oriel JD. Natural history of genital warts. Br J Venereal Dis. 1971;131-52.

  61. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neo-plasias and in genital warts. Med Microbiol Immunol. 2004;193:35-44.

  62. Wright JD, Herzog TJ. Human papillomavirus: emerging trends in detection and management. Curr Womens Health Rep. 2002;2:259-65.

  63. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32S:S16-S24.

  64. Zur Hausen H. Human papillomavirus and their possible role in squamous cell carcinomas. Microbial Immunol. 1977;78:1-30.

  65. Bosch FX, Sanjose S. Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3-13.

  66. Micali G, Nasca MR, Innocenzi D, Schwartz RA. Penile cancer. J Am Acad Dermatol. 2006;54(3):369-91.

  67. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27.

  68. Ferrandiz-Pulido C, Masferrer E, de Torres I, LLoveras B, Hernandez-Losa J, Mojal S. Identification and genotyping of human papilloamvirus in a Spanish cohort of penile squamous cell carcinomas: correlation with pathological subtypes, p16(INK4a) espression and prognosis. J Am Acad Dermatol. 2013;68:73-82.

  69. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357:1831-36.

  70. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-78.

  71. Levine RU, Crum CP, Herman E, Silvers D, Ferenczy A, Richart RM. Cervical papillomavirus and intraepithelial neoplasia: a study of the male sexual partner. J Obstetrics Gynaecol. 1984;64:16-20.

  72. McCance DJ, Kalache A, Ashdown K, Andrade L, Menezes F, Smith P, Doll R. Human papillomavirus types 16 and 18 in carcinomas of the penis from Brazil. Int J Cancer. 1986;37:55-59.

  73. Gross G, Ikenberg H, de Viliiers EM, Schneider A, Wagner D, Gissmann L. Bowenoid papulosis: a venereally transmitted disease as reservoir for HPV 16. In: Zur Hausen H, Peto P, editors. Origins of female genital cancer: virological and epidemiological aspects. (Banbury Report). New York: Cold Spring Harbor; 1986. pp. 140-165.

  74. Villa LL, Lopes A. Human papillomavirus DNA sequences in penile carcinomas in Brazil. Int J Cancer. 1986;37:853-55.

  75. Lont AP, Kroon BK, Horenblas S, Gallee MP, Berkhof J, Meijer CJ, Snijders PJ. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer. 2006;119(5):1078-81.

  76. Van Baarle, Hovenkamp E, Dukers NH, Renwick N, Kersten MN, Goudsmit J, Courinho RA, Miedema F, Van Oers MH. High prevalence of Epstein-Barr virus type 2 among homosexual men is caused by sexual transmission. J Infect Dis. 2000;181:2045-49.

  77. Crawford DH. Biology and disease associations of Epstein-Barr virus. Phil Trans Royal Soc London. Series B: Biol Sci. 2001;356:461-73.

  78. Epstein MA, Achong BG, Barr YM. Virus particles in culture lymphoblasts from Burkitt's lymphoma. Lancet Infect Dis. 1964;61(3):249-55.

  79. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumors. Oncogene. 2003;22:5108-21.

  80. Rickinson A, Kieff E. Epstein-Barr virus. In: Fields' virology, 3rd edition. Philadelphia: Lippincott-Raven; 2001. Chapter 75.

  81. Faulkner GC, Krajewski AS, Crawford DH. The ins and outs of EBV infection. Trends Microbiol. 2000;8(4): 185-89.

  82. Dambaugh T, Wang F, Hennessy K, Woodland E, Rickinson A, Kieff E. Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells. J Virol. 1986;59:453-62.

  83. Buisson M, Morand P, Genoulaz O, Bourgeat MJ, Micoud M, Seigneurin JM. Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection. J General Virol. 1994;75:431-37.

  84. Cohen JI, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A. 1989;86: 9558-62.

  85. Rickinson A, Young L, and Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus transformed B cells. J Virol. 1987;61:1310-1317.

  86. Gratama JW, Ernberg I. Molecular epidemiology of Epstein-Barr virus infection. Adv Cancer Res. 1995; 67:197-255.

  87. Zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the naso-pharynx. Nature. 1970;228:1056-58.

  88. Ziegler JL, Drew WL, Miner RC, Mintz L, Rosenbaum E, Lennette E, Shillitoe E, Casavant C, Drew WL, Mintz L, Gershow J, Greenspan J, Beckstead J. Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet. 1982;2:631-33.

  89. Weiss LM, Strickler JG,Warnke RA, Purtilo DT, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol. 1987;129:86-91.

  90. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med. 1989;320:502-6.

  91. Farrell PJ, Cludts I, Stuhler A. Epstein-Barr virus genes and cancer cells. Biomed Pharmacother. 1997;51:258-67.

  92. Greenspan JS, Greenspan D, Lennette ET, Abrams DI, Conant MA, Petersen V, Freese UK. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS association lesion. N Engl J Med. 1985;313:1564-71.

  93. Naher H, Gissmann L, Freese UK, Petzoldt D, Helfrich S. Subclinical Epstein-Barr virus infection of both the male and female genital tract-indication for sexual transmission. J Investigative Dermatol. 1992;98:791-793.

  94. Zur Hausen H. Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating eventes. Lancet. 1982;2:1370-72.

  95. Tao Q, Young LS, Woodman CBJ, Murray PG. Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. J Frontiers Biosci. 2006;11:2672-713.

  96. Moses S, Bailey RC, Ronald AR. Male circumcision: assessment of health benefits and risks. Sex Transmit Infect. 1998;74:368-73.

  97. Schoen EJ, Oehrli M, Colby C, Machin G. The highly protective effect of newborn circumcision against invasive penile cancer. Pediatrics. 2000;105(3):E36.

  98. Harish K, Ravi R. The role of tobacco in penile carcinoma. Brazil J Urol. 1995;75(3):375-77.

  99. Lazcano-Ponce E, Herrero R, Munoz N, Hernandez-Avila M, Salmeron J, Leyva A, Meijer CJ, Walboomers JM. High prevalence of human papillomavirus infection in Mexican males: comparative study of penile-urethral swabs and urine samples. Sex Transmit Infect. 2001;28:277-80.

  100. Franceschi S, Castellsague X, Dal Maso L, Smith JS, Plummer M, Ngelangel C, Chichareon S, Eluf-Neto J, Shah KV, Snijders PJF, Meijer CJLM, Bosch FX, Munoz N. Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer. 2002;86:705-11.

  101. Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Giuliano AR. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transmit Dis. 2004;31:601-7.

  102. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, Kong HJ, Rha SH, Jung SI, Kim JI, Jung KY, Van Doorn LJ, Quint W. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis. 2004;190:468-76.

  103. Van Doornum GJ, Prins M, Juffermans LH, Hooykaas C, Van den Hoek JA, Coutinho RA, Quint WG. Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple sexual partners: a prospective study. Genitourinary Med. 1994;70:240-46.

  104. Hippelainen M, Syrjanen S, Koskela H, Pulkkinen J, Saarikoski S, Syrjanen K. Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transmit Dis. 1993;20:321-28.

  105. Hakenberg OW, Drager D, Erbersdobler A. Pathology, molecular biology, and prognosis of penile squamous cell carcinoma: what can we learn from the specimen? Eur Urol. 2018;17(6):138-45.

  106. Viscidi RP Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, Rodriguez AC, Sherman ME, Wang S, Clayman B, Burk RD. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarker Prevent. 2004;13:324-27.

  107. Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee JH, Abrahamsen M, Harris RB. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis. 2008 Sep 15;198(6):827-35.

  108. World Health Organization. 1st WHO international standard for Epstein-Barr virus for nucleic acid amplification techniques. 2014. [Last updated 2014 Sept 10]. Available from: https://www.nibsc.org/documents/ifu/09-260.pdf.

  109. Bechert CJ, Schnadig VJ, Payne DA, Dong J. Monitoring of BK viral load in renal allograft recipients by real-time PCR assays. Am J Clin Pathol. 2010;133:242-50.

  110. Skinner DG, Leadbetter WF, Kelley SB. The surgical management of squamous cell carcinoma of the penis. J Urol. 1972;107:273-78.

  111. Puras-Baez A, Rivera-Herrera J, Miranda G. Role of superficial inguinal lymphadenectomy in carcinoma of the penis. J Urol. 1995;153:246A.

  112. Favorito LA, Nardi AC, Ronalsa M, Zequi SC, Sampaio FJB, Glina S. Epidemiologic study on penile cancer in Brazil. Int Brazil J Urol. 2008;34:587-93.

  113. Giuliano A, Palefsky J. Quadrivalent HPV vaccine efficacy against male genital disease and infection. Presented at the 25th International Papillomavirus Conference. 2009 May 8-14; Malmo, Sweden; Abstract 0:01-07.

  114. Petaja T, Keranen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M, Levanen H, Tocklin T, Godeaux O, Lehtinen M, Dubin G. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccines in healthy boys aged 10-18 years. J Adolescent Health. 2009;44:33-40.

  115. Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26:201-9.

  116. Palefsky J, Giuliano AR. Quadrivalent HPV vaccine efficacy in men having sex with men. Presented at the 25th International Papillomavirus Conference. May 8-14, 2009; Malmo, Sweden; Abstract P27-01.

  117. Wolbarst AL. Circumcision and penile cancer. Lancet. 1932;1:150-53.

  118. Bissada NK, Morcos RR. El-Senoussi. Post-circumcision carcinoma of the penis. I. Clinical aspects. J Urol. 1986;135:283-85.

  119. Magoha GA, Kaale RF. Epidemiological and clinical aspects of carcinoma of penis at Kenyatta National Hospital. East African Med J. 1995;72:359-61.

  120. Seyam RM, Bissada NK, Mokhtar AA, Mourad WA, Aslam M, Elkum N, Kattan SA, Hanash KA. Outcome of penile cancer in circumcised men. J Urol. 2006;175: 557-61.

  121. Barbosa Junior AA, Athanazio PRF, Oliveira B. Cancer do penis: estudo de sua patologia geografica no Estado da Bahia, Brasil. Revista Saude Publica. 1984;18:429-35.

  122. Albero G, Castellsague X, Giuliano AR, Bosch FX. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transmit Dis. 2012;39:2.

  123. Prue G, Lawler M, Baker P, Warnakulasuriya S. Human papilomavirus (HPV): making the case for immunisation for all. Oral Dis. 2017;23:726-30.

  124. Zur Hausen H. The search for infectious causes of human cancers: where and why. Virology. 2009;392:1-10.

CITADO POR
  1. Majewska Anna, Mlynarczyk-Bonikowska Beata, 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?, International Journal of Molecular Sciences, 23, 7, 2022. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain